Susquehanna International Group
RLAY icon

Susquehanna International Group’s Relay Therapeutics RLAY Stock Holding History

Susquehanna International Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,600
Closed -$91.9K – 13408
2025
Q3 		$91.9K Buy
+17,600
New +$67.1K ﹤0.01% 11614
2024
Q4 		– Sell
-62,300
Closed -$441K – 13050
2024
Q3 		$441K Buy
+62,300
New +$465K ﹤0.01% 8773
2023
Q3 		– Sell
-67,000
Closed -$842K – 12817
2023
Q2 		$842K Buy
67,000
+51,600
+335% +$642K ﹤0.01% 7092
2023
Q1 		$254K Sell
15,400
-23,800
-61% -$427K ﹤0.01% 10086
2022
Q4 		$586K Sell
39,200
-43,000
-52% -$823K ﹤0.01% 7433
2022
Q3 		$1.84M Sell
82,200
-14,700
-15% -$323K ﹤0.01% 5087
2022
Q2 		$1.62M Buy
96,900
+89,900
+1,284% +$1.93M ﹤0.01% 5352
2022
Q1 		$210K Buy
7,000
+200
+3% +$4.85K ﹤0.01% 11126
2021
Q4 		$209K Sell
6,800
-17,600
-72% -$556K ﹤0.01% 11356
2021
Q3 		$769K Buy
+24,400
New +$821K ﹤0.01% 8239

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Susquehanna International Group's RLAY Position: Q1 2026 in Review

Susquehanna International Group reduced its Relay Therapeutics (RLAY) stake by 34% in Q1 2026, selling an estimated $678K and leaving 147,158 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #6953.

Susquehanna International Group first reported a position in RLAY in Q4 2020 and has held it in 22 quarters since. The position peaked at $4.2M in Q1 2023. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Susquehanna International Group held 147,158 shares of Relay Therapeutics worth $1.46M as of Q1 2026.
  • Susquehanna International Group sold 75,771 Relay Therapeutics shares in Q1 2026, an estimated $678K.
  • Relay Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6953 holding.
  • Susquehanna International Group first reported a position in Relay Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Susquehanna International Group's Relay Therapeutics position peaked at $4.2M in Q1 2023.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.